Retaspimycin hydrochloride was evaluated in clinical trials for non-small cell lung cancer (NSCLC) [16] and for ERBB2-positive breast cancer [73], but it failed to meet the criteria for study expansion. Here, ERBB2 is linked to breast cancer.